ClinicalTrials.gg
Active, not recruitingNCT05026827YogaUpdated Oct 9, 2026

Iyengar Yoga for Prolonged Grief Disorder

An interventional study of Iyengar Yoga and Socialization Control in Prolonged Grief Disorder, sponsored by Medical College of Wisconsin. Active, not recruiting at 1 site in United States. Open to participants aged 40 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-09.

Sponsored by Medical College of Wisconsin · Not applicable, Interventional, and Other

How we know

Updated Oct 9, 2026Primary completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
68
Allocation
Randomized
Ages
40 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 15 studies in Prolonged Grief Disorder with a site in United States — 4 open to participants now, 5 under way, none of them phase 3. Prolonged Grief Disorder · United States.

Enrollment
6th of 14
68 · median 42
Started
2021
with 2 others
No phase
10 of 15
3 open now
Registered
8th of 15
by date
Lead sponsor
2 of 15
Medical College of Wisconsin

Among the 15 studies in Prolonged Grief Disorder with a site in United States, this one is the 6th largest by enrollment of the 14 interventional ones that give a count, is one of 3 that started in 2021, is one of 10 with no phase, and was the 8th registered.

Prolonged Grief Disorder

40 studies on the registry are indexed under Prolonged Grief Disorder; 14 are open to participants now.

Browse Prolonged Grief Disorder studies →

Open to participants now

4 of the 15 studies in Prolonged Grief Disorder with a site in United States are open now. Recruiting first, the newest first:

All 4 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 9 Prolonged Grief Disorder studies recruiting now, 7 set no upper age limit and 2 stop at 75 or younger; none take children under 18; 4 take healthy volunteers.

This study: 40 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 15 studies in Prolonged Grief Disorder with a site in United States, or all of them as a file.
02

Study summary

Experiencing the death of a loved one is inevitable for older adults. Before the coronavirus disease 2019 (COVID-19) pandemic, over 2.5 million people died annually in the United States, including 52,000 in Wisconsin alone, and COVID-19 has added to this toll. Each person who dies leaves an average of five grieving people behind. Most grieving older adults are resilient and recover their pre-loss functioning within one year. However, in about 10%, acute grief becomes protracted and debilitating, leading to the development of prolonged grief disorder (PGD), a clinically diagnosable mental health condition. PGD in older adults increases the risk for poorer medical, mental health, and cognitive outcomes; lower quality of life; disability; premature mortality; and suicide. Despite the magnitude of this problem, the neurobiology of PGD in older adults is poorly understood. By using Iyengar Yoga (IY) as a probe for PGD neurobiology, this pilot project aims to address this critical gap.

Read the detailed description

Our goal is to conduct a pilot study to examine in PGD the modulating effects of 10-week IY on circulating endocannabinoid and emotion processing brain circuit, and the associations between biological changes and clinical response.

03

Conditions studied

  • Prolonged Grief Disorder
04

Who can participate

Ages eligible
40 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female greater than or equal to 40 years of age
  • Bereavement >6 months
  • Score greater than or equal to 25 on the Inventory of Complicated Grief (ICG)
  • Presence of PGD (subsyndromal and syndromal)
  • Adequate visual and auditory acuity

Exclusion criteria

Exclusion Criteria:

  • Delirium/unstable medical conditions
  • Lifetime history of neurological illnesses: seizures, stroke, dementia of any etiology, severe head injury, brain tumor or surgery
  • Serious back, joint or neck injuries within the past 3 months
  • Currently practicing yoga
  • Gross structural abnormalities on T1-weighted images
  • Lifetime history of the following psychiatric disorders: bipolar or psychotic disorders, including psychotic depression
  • Current alcohol/drug abuse or dependence
  • Magnetic resonance imaging (MRI)
  • Acute suicidality
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
68 participants (actual)

Study arms

  • Experimental
    Iyengar Yoga

    Participants will engage in 10 weekly IY classes

    Other: Iyengar Yoga

  • Active comparator
    Socialization Control

    Participants will engage in 10 weekly socialization control group sessions

    Other: Socialization Control

  • No intervention
    Healthy Comparison Group

    A group of participants will also be followed for 10 weeks

Interventions

  • OtherIyengar Yoga

    Participation in Iyengar Yoga classes

  • OtherSocialization Control

    Participation in socialization control group sessions

06

What researchers measure

Primary outcomes

  1. Change in circulating endocannabinoid concentrations

    Change in circulating endocannabinoids from baseline to post-intervention

    Time frame: 10 weeks

Secondary outcomes

  1. Change in neural activity measured using Functional magnetic resonance imaging (fMRI)

    Change in neural activity from baseline to post-intervention

    Time frame: 10 weeks

  2. Inventory of Complicated Grief (ICG) scale score change

    ICG score ranges from 0 to 76 (higher scores indicate worse outcome)

    Time frame: 10 weeks

07

Study locations

1 site
08

References and documents

Publications

  • Goveas JS, Hwang G, McAuliffe TL, Blair NP, Webber A, Claesges SA, Murphy LM, Chandler K, Reynolds CF, Hainsworth KR. Iyengar yoga and health education interventions for prolonged grief disorder in later life: feasibility of a randomized controlled pilot trial. Sci Rep. 2025 Dec 24;15(1):44604. doi: 10.1038/s41598-025-28397-5. PubMed 41444366 ↗

Individual participant data

Plan to share: No

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2021 (actual). Primary completion is estimated for Dec 2026, 64 months after the start.

Of 27 interventional studies with no phase under Prolonged Grief Disorder, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 57. This study's planned 64 months is above that.

Primary completion moved once since we started tracking on Sep 25, 2026: Aug 2026 → Dec 2026, on Oct 9, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Aug 24, 2021
First posted
Aug 30, 2021
StartActual
Aug 30, 2021
Primary completionEst.
Dec 2026was Aug 2026
CompletionEst.
Dec 2026
Last update
Oct 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Aug 2026→Dec 2026
Oct 9, 2026
Show all 1 update
  1. Oct 9, 2026
    Primary completion Aug 2026→Dec 2026

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05026827
Responsible party
Joseph Goveas (Professor, Medical College of Wisconsin) — Principal investigator
First posted
Aug 30, 2021
Start date
Aug 30, 2021
Primary completion
Dec 2026 (estimated)
Completion
Dec 2026 (estimated)
Last update
Oct 9, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion